Literature DB >> 11159023

Type 2 rhinovirus infection of cultured human tracheal epithelial cells: role of LDL receptor.

T Suzuki1, M Yamaya, M Kamanaka, Y X Jia, K Nakayama, M Hosoda, N Yamada, H Nishimura, K Sekizawa, H Sasaki.   

Abstract

To examine the role of the low-density lipoprotein (LDL) receptor on minor group human rhinovirus (RV) infection, primary cultures of human tracheal epithelial cells were infected with a minor group (RV2) or a major group (RV14) RV. Viral infection was confirmed by showing with PCR that viral titers in supernatants and lysates from infected cells increased with time. RV2 and RV14 increased expression of mRNA and protein of the LDL receptor on the cells and the cytokine production. RV2 induced activation of transcription factors SP1 and nuclear factor-kappaB (NF-kappaB). An antibody to the LDL receptor inhibited RV2 infection and RV2-induced cytokine production without an effect on RV14 infection and RV14-induced cytokine production. These findings imply that RV2 upregulates LDL receptor expression on airway epithelial cells, thereby increasing susceptibility to minor group RV infection. LDL receptor expression and cytokine production may be mediated, in part, via activation of transcription factors by RV2. These events may be important in airway inflammation after minor group RV infection in asthma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159023     DOI: 10.1152/ajplung.2001.280.3.L409

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  13 in total

1.  Human rhinovirus attenuates the type I interferon response by disrupting activation of interferon regulatory factor 3.

Authors:  Tao Peng; Swathi Kotla; Roger E Bumgarner; Kurt E Gustin
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

2.  Identification of a Novel Inhibitor of Human Rhinovirus Replication and Inflammation in Airway Epithelial Cells.

Authors:  Zhonghui Yang; Yury A Bochkov; Dennis R Voelker; Matthew W Foster; Loretta G Que
Journal:  Am J Respir Cell Mol Biol       Date:  2019-01       Impact factor: 6.914

Review 3.  Rhinoviruses and Their Receptors: Implications for Allergic Disease.

Authors:  Yury A Bochkov; James E Gern
Journal:  Curr Allergy Asthma Rep       Date:  2016-04       Impact factor: 4.806

4.  Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells.

Authors:  Christopher A Hewson; Alice Jardine; Michael R Edwards; Vasile Laza-Stanca; Sebastian L Johnston
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Levofloxacin inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells.

Authors:  Mutsuo Yamaya; Hidekazu Nishimura; Yukimasa Hatachi; Hiroyasu Yasuda; Xue Deng; Takahiko Sasaki; Katsumi Mizuta; Hiroshi Kubo; Ryoichi Nagatomi
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

Review 6.  Rhinoviruses in the pathogenesis of asthma.

Authors:  Nikolaos G Papadopoulos; Stelios Psarras
Journal:  Curr Allergy Asthma Rep       Date:  2003-03       Impact factor: 4.919

7.  Apolipoprotein mimetic peptides: a new approach for the treatment of asthma.

Authors:  Xianglan Yao; Michael P Vitek; Alan T Remaley; Stewart J Levine
Journal:  Front Pharmacol       Date:  2012-03-09       Impact factor: 5.810

8.  Virus infection-induced bronchial asthma exacerbation.

Authors:  Mutsuo Yamaya
Journal:  Pulm Med       Date:  2012-08-23

9.  Productive entry pathways of human rhinoviruses.

Authors:  Renate Fuchs; Dieter Blaas
Journal:  Adv Virol       Date:  2012-11-26

10.  Major and minor group rhinoviruses elicit differential signaling and cytokine responses as a function of receptor-mediated signal transduction.

Authors:  Bryce A Schuler; Michael T Schreiber; Luyuan Li; Michal Mokry; Megan L Kingdon; Dana N Raugi; Cosonya Smith; Chelsea Hameister; Vincent R Racaniello; David J Hall
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.